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Abstract
Systemic administration of epidermal growth factor (EGF)
in neonatal rats results in reduced body weight gain and
decreased circulating levels of IGF-I, suggesting its in-
volvement in EGF-induced growth retardation.
We investigated the effect of EGF and/or IGF-I admin-
istration for 7 days on circulating IGF-I and IGFBP levels
and hepatic and renal IGF-system mRNA expression
profiles in adult female rats. EGF administration
(30 µg/rat/day) did not influence body weight, liver or
kidney weight. In contrast, IGF-I (400 µg/rat/day) and
EGF/IGF-I administration increased both body weight
and kidney weight. Also, serum IGF-I and the 30 kDa
IGFBPs (IGFBP-1 and -2) were significantly increased in
these groups. Serum IGFBP-3 levels increased in the
IGF-I group along with increased hepatic IGFBP-1 and -3
mRNA levels. In contrast, in the EGF administration
group serum IGFBP-3 levels were significantly decreased;
however, the mRNA levels remained unchanged. In the
EGF/IGF-I administration group, serum IGF-I and
IGFBP-3 levels were significantly lowered when com-
pared with the IGF-I administration group. This was in
contrast to the effect on kidney weight increase that was
identical for the IGF-I and EGF/IGF-I groups. The
decrease in serum IGFBP-3 was not reflected at the
hepatic IGFBP-3 mRNA level. IGFBP-3 expression
might be regulated at a post-transcriptional level although
EGF induced IGFBP-3 proteolysis could not be demon-
strated in vitro.
We conclude that EGF administration reduced serum
IGFBP-3 whereas IGF-I administration increased the level
of IGFBP-3 and IGF-I and resulted in an increased body
and kidney weight in adult female rats.
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Introduction
Insulin-like growth factor I (IGF-I) is a multifunctional
growth factor produced in a variety of body fluids and
tissues including liver and kidney. IGF-I is a member of
the IGF-system that also consists of IGF-II, two types
of IGF receptor and six different IGF binding proteins
(IGFBPs) (Kelley et al. 1996). Furthermore, four IGFBP
related proteins have been described (Baxter et al. 1998).
The IGFBPs are abundantly present in the circulation,
organs and tissues and act as major modulators of IGF
action by transporting the IGFs to their sites of action and
controlling the bioavailability of the IGFs to their surface
receptors (Kelley et al. 1996). However, little is known
about the in vivo regulation of their production.
The epidermal growth factor (EGF) belongs to a family
of growth factors that regulate cell proliferation, migration
and differentiation through binding to receptor tyrosine
kinases on target cells (Miettinen 1997). EGF has been
shown to act as a mitogen as well as a differentiation factor
for many cell types (Bonassar & Trippel 1997). It is present
in the circulation at very low concentrations that, never-
theless, also elicit cellular responses in vitro (Bujia et al.
1993, Murakami et al. 1994). In addition, the kidney is
thought to be the major site of EGF synthesis in mammals
(Fisher et al. 1989).
Given the large number of hormones, cytokines and
growth factors present in the circulation, organs and
tissues, interactions between growth factor families are a
field of growing interest. Several studies have focused on
the interaction between the EGF and IGF systems in vitro.
EGF addition to isolated rat renal collecting duct cells
increased IGF-I mRNA levels 3-fold (Rogers et al. 1991).
EGF addition to human keratinocytes in primary culture
reduced IGFBP-3 mRNA levels to 50% of control values
whereas IGF-I addition had no effect (Edmondson et al.
1999). Furthermore, addition of EGF to rat hepatocytes in
primary culture had a dose-dependent stimulatory effect
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on IGF-I and IGFBP-1 production (Barreca et al. 1992).
Accordingly, IGF-I modulates the EGF receptor action in
keratinocyte proliferation (Krane et al. 1991), whereas
EGF stimulates IGF-I biosynthesis in the liver and in the
kidneys. However, only a few studies have examined these
interactions during systemic administration in vivo (Frystyk
et al. 1996, Vinter-Jensen et al. 1996).
In the present paper we investigated the effects of short
term (7 days) EGF and/or IGF-I administration on the
expression of the circulating, hepatic and renal IGF-system
genes in young adult female rats.
Materials and Methods
Animals
Female Wistar rats (mean body weight 190 g) obtained
from our own breeders (Department of Pathology, Aalborg
Hospital, Denmark) were used in the study. The animals
were housed individually in cages on white special
spanwall bedding. They were fed a standard laboratory
diet (No. 1310, Lage, Germany), had free access to water
and were kept at constant temperature (21 C), humidity
(555%) and at a ratio of 12-h light: 12-h darkness cycle
(0600–1800 h light). The study complied with Danish
regulations for care and use of laboratory animals.
Study design
The rats were randomly allocated into four groups of eight
animals:
(1) Placebo control: animals infused with 0·1 M acetic
acid.
(2) EGF group: animals infused with 30 µg/rat/day
human recombinant (hr) EGF.
(3) IGF-I group: animals infused with 400 µg/rat/day
hrIGF-I.
(4) EGF/IGF-I group: animals infused with 30 µg/rat/
day hrEGF and 400 µg/rat/day hrIGF-I.
The growth factors were dissolved in 0·1 M acetic acid
and delivered by osmotic minipumps (Model 2002, Alzet,
Alza, Palo Alto, CA, USA) subcutaneously implanted on
the back of each rat under light ether anesthesia. The
infusion rate was 1 µl/h for 7 days.
Treatment was initiated at day 0. The animals were
weighed at days 0, 2, 4, and 7. At day 7 the animals were
anesthetized with pentobarbital (50 mg/kg i.p.). Non-
fasting blood samples were collected from the retrobulbar
plexus through heparinized capillary tubes under light
ether anesthesia. On day 7 the animals were decapitated,
the serum samples were kept at 80 C for later analysis.
The left kidney and liver were removed, weighed and
snap frozen in liquid nitrogen.
Serum IGF-I
Serum IGF-I was extracted using acid ethanol (30 µl
serum and 750 (µl acid ethanol) in order to determine total
levels of circulating IGF-I as described previously
(Daughaday et al. 1980). Serum extracts were diluted
1:200 in assay buffer (40 mmol/l phosphate pH 8·0,
0·6 mmol/l sodium merthiolate and 5% (w/v) human
serum albumin). IGF-I concentrations were analyzed by
an in-house IGF-I RIA using a polyclonal rabbit antibody
(Nichols Institute Diagnostics, San Capistrano, CA, USA)
and rhIGF-I as standard (Amgen Biologicals, CA, USA,
purchased from Amersham International, Amersham,
Bucks, UK). Mono-iodinated rhIGF-I (125I-(Tyr31)
IGF-I) was obtained from Novo Nordisk A/S Bagsvaerd,
Denmark. The intra-assay and inter-assay coefficients of
variation were 5% and 10% respectively.
Serum IGFBPs
SDS-PAGE and Western ligand blotting (WLB) analyses
were executed according to the method of Hossenlopp
(Hossenlopp et al. 1986) as described previously (Flyvbjerg
et al. 1992).
Gene-expression of IGF system genes (mRNA) in tissues
Gene-expression of IGFBP 1–4 and -5 (renal) was
measured by Northern blot analysis. Total RNA was
extracted from kidney and liver samples by the guanidin-
ium thiocyanate method (Chomczynski & Sacchi 1987).
Glyoxilated-RNA samples were electrophoresed in 1%
agarose gels submerged in 10 mM sodium phosphate (pH
7·2) and transferred to nylon membranes (Hybond N+,
Amersham, Hertogenbosch, The Netherlands). Filters
were hybridized with 1–2106 c.p.m. per ml of 32P-
labeled cDNA fragments encoding for each of the six
mouse IGFBPs (Schuller et al. 1994) and 18S rRNA at
65C, according to the method of Church & Gilbert
(1984).
Gene expression of IGFBP-5 (hepatic), IGFBP-6,
IGF-I, -II, IGF-I receptor, and the IGF-II/mannose-6-
phosphate (Man-6-P) receptor was below Northern blot
detection levels and was measured by a semi-quantitative
reverse transcriptase (RT) PCR approach using 18S
internal standards (Ambion, Austin, TX, USA). One
microgram of total RNA was reverse transcribed with
200 units of Moloney murine leukaemia virus
(M-MLV) reverse transcriptase (Gibco BRL, Breda, The
Netherlands) and primed with 3-primers specific for the
IGF-system genes. The RT reaction was carried out in
20 µl (total volume) cDNA buffer (75 mM KCl, 3 mM
MgCl2, 50 mM Tris–HCl, pH 8·3), 10 mM DTT, 1 mM
of each deoxy-NTP, and 20 U of RNAse guard (Phar-
macia, Roosendaal, The Netherlands). The reaction mix
was incubated for 1 h at 37 C, heated to 95 C for 5 min,
and then diluted to 100 µl. The PCR reaction was carried
out with 2 µl of diluted RT mixture in PCR buffer
(50 mM KCl, 1·5 mM MgCl2, and 20 mM Tris–HCl, pH
8·3), 25 pmol forward and reverse primers and 1U of
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Hi-Taq DNA Polymerase (Bioprobe Systems, France).
PCR reactions were performed separately and the
products analyzed on 1% agarose gel and transferred to
nylon membranes (Hybond N+, Amersham). Filters were
hybridized with 1–2106 c.p.m. per ml 32P-labeled
cDNA fragments encoding for the corresponding IGF-
system genes and 18S rRNA. Oligonucleotide primers
designed for the amplification were purchased from
Pharmacia Biotech and were as follows: IGFBP-5: sense
primer, 5-TTGCCTCAACGAAAAGAGC-3; antisense
primer, 5-AGAATCCTTTGCGGTCACA (size of cor-
responding PCR fragment: 377 bp). IGFBP-6: sense
primer, 5-GTCTACAGCCCTAAGTGCGCCCCAG-
3; antisense primer, 5-CACAGTTTGG-CACATAGA
GCCCAC (size of corresponding PCR fragment: 345 bp).
IGF-I: sense primer 5-AAAATGACCGCACCTCC
A-AC-3; antisense primer, 5-AGATCACAGCTCC
GGAAGCA-3 (size of corresponding PCR fragment:
299 bp). IGF-II: sense primer 5-GCCCCGGAGAGAC
TCTGTGCG-3; antisense primer, 5-GCCCACGGGG
TATCTGGGG-AA-3 (size of corresponding PCR frag-
ment: 253 bp). IGF-I receptor: sense primer, 5-GAG
TACAACTACCGCTGCTGGAC-3; antisense primer,
5-AGGGGCCTTCACAGGGGA-TACA-3 (size of
corresponding PCR fragment: 380 bp). IGF-II/Man-6-P
receptor: sense primer, 5-CCAGTTTCTTCTGCCAG
CAAGGG-3; antisense primer, 5-GCTCCTCTCC
AAG-AGCCTCTAC-3 (size of corresponding PCR
fragment: 330 bp).
Quantification
Autoradiographs of ligand blots were scanned using a laser
densitometer (Shimadzu model CS 90001 PC, Shimadzu
Europe GmbH, Duisburg, Germany) and the relative
densities of the bands expressed in arbitrary absorbency
units per square millimeter (AU/mm2). Northern blots
were scanned on a Phosphor Imager (Molecular
Dynamics, Sunnyvale, CA, USA) and quantified using
ImageQuant software (Molecular Dynamics, Sunnyvale,
CA, USA). All measured IGF-system results were ex-
pressed relative to 18S rRNA levels, as mean...,
with n indicating the number of animals studied.
Statistical analysis
Data were examined for distribution, variance homogen-
eity (F-test) and analyzed using Student’s unpaired t-test if
appropriate. Otherwise, the significance of difference was
compared by one-way analysis of variance (ANOVA)
followed by pair-wise comparisons with the least signifi-
cant difference (LSD)-method. The interaction between
EGF and IGF-I administration was compared by 2-way
ANOVA followed by a regression model to assess the
significance of the contribution of EGF and IGF-I. All data
are expressed as mean..., with n indicating the
number of rats studied and P-values less than 5% are
considered significant.
Results
Body weight
In Table 1A the body weights of the different study groups
at the beginning (day 0) and end (day 7) of the exper-
imental period are shown. The mean body weights on day
0 were between 190 and 191 g with no differences
between the groups. At day 7, body weights of control
animals and rats treated with EGF were identical. Rats
treated with IGF-I or EGF/IGF-I significantly increased
weight to 1973 g (P=0·04 day 0 versus day 7) and
2032 g (P=0·002 day 0 versus day 7) respectively. In
addition, the EGF/IGF-I treated group demonstrated a
significantly increased weight gain when compared
with the group that received EGF alone (EGF versus
EGF/IGF-I, P=0·002).
Table 1 (a) Body weight at the start (day 0) and end (day 7) of the study, liver weight at day 7 and kidney weight at day 7 (all
meanS.E.M., n=8) in adult female rats treated with placebo, EGF, IGF-I or EGF+ IGF-I. (b) Liver and kidney weights, expressed as
percentage of total body weight and related to placebo control animals
(a)
Placebo control EGF IGF-I EGF+IGF-I
Body weight (g), day 0 190·60·4 190·50·4 190·50·4 190·30·3
Body weight (g), day 7 191·72·1 191·02·3 196·62·7* 202·62·2**#
Liver weight (mg), day 7 3970347 4528591 4225302 4236386
Kidneys weight (mg), day 7 117719 121316 145615*** 151923***
(b)
Placebo control EGF IGF-I EGF+IGF
Liver 100 114 104 101
Kidneys 100 104 121*** 123***
*P=0·04, **P=0·002, ***P=<0·001, when compared with placebo controls.
#P=0·002, when compared with the IGF-I infusion group.
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Liver and kidney weights
At the end of the treatment the weights of the liver and
kidneys were determined (Table 1A).
When compared with placebo control, infusion regi-
mens did not demonstrate a significant effect on liver
weight. In kidneys, EGF infusion alone did not result in an
organ-specific weight increase while IGF-I and EGF/
IGF-I treatments significantly increased the weight to
121% (P<0·001) and 123% (P<0·001) of the control
weight, respectively (Table 1B).
Serum IGF-I
By the end of the infusion period serum IGF-I levels
were determined in all infusion groups (Table 2). In the
EGF-treated group serum IGF-I levels were unchanged
(39625 µg/l). In the IGF-I treated group the IGF-I
levels were significantly increased to 153792 µg/l
(P<0·001). In the group treated with EGF/IGF-I IGF-I
levels significantly increased to 96494 µg/l (P=0·01)
However, compared with the IGF-I infusion group the
increase in IGF-I was significantly lower in the EGF/
IGF-I group (P=0·01).
Serum IGFBPs
Using WLB four distinct bands were obtained. A double
band at 42 and 38 kDa represents IGFBP-3, a single band
at 30 kDa represents IGFBP-1 and -2 and a 24 kDa band
represents IGFBP-4 (as described previously) (Flyvbjerg
et al. 1992).
In the EGF-treated group IGFBP-3 levels were signifi-
cantly lowered to 44% of control values (P<0·001)
whereas in the IGF-I treated group IGFBP-3 levels were
significantly increased to 181% of control values
(P<0·001). In the EGF/IGF-I-treated group the circu-
latory IGFBP-3 values remained unchanged (Table 2).
Circulating 30 kDa IGFBPs (IGFBP-1 and -2) were
unchanged in the EGF treatment group. However, in the
IGF-I and EGF/IGF-I groups the 30 kDa IGFBPs
(IGFBP-1 and -2) were significantly increased to 247%
and 305% of control values (both P=0·007). IGF-I infu-
sion did not significantly modify IGFBP-4 levels, whereas
EGF and EGF/IGF-I infusion demonstrated significantly
increased IGFBP-4 levels (165% and 182% of control
values; P=0·02 and P=0·008 respectively) (Table 2).
Hepatic IGF system expression
Compared with the mRNA expression in control rats,
EGF infusion did not significantly modify hepatic IGF
system mRNA levels (Fig. 1).
IGF-I-infused animals demonstrated significantly
increased hepatic IGFBP-1 (P=0·03) and IGFBP-3
(P=0·001) mRNA levels when compared with placebo
infused rats (Fig. 1A), whereas IGFBP-5 mRNA levels
were significantly decreased in the IGF-I infusion group
(P=0·05) (Fig. 1B). IGFBP-5 mRNA levels in the
EGF/IGF-I infusion group were the result of a significant
interaction between EGF and IGF-I that, however, could
not be significantly attributed to EGF and/or IGF-I.
In the EGF/IGF-I infusion group, hepatic IGFBP-1, -2
and -3 mRNA levels were significantly increased
(P=0·03, P=0·01 and P=0·001 respectively) (Fig. 1).
IGFBP-2 mRNA levels in the EGF/IGF-I infusion group
were the result of a significant interaction between EGF
and IGF-I that could be significantly attributed EGF
(P<0·001) and IGF-I (P<0·02).
Hepatic IGF-II and IGF-I receptor mRNA could not
be reliably quantified in any of the groups.
Renal IGF system expression
Compared with the expression levels in control rats, EGF
infusion did not change renal mRNA levels of most of the
IGF system genes. Only IGFBP-4 demonstrated signifi-
cantly increased (P=0·03) whereas IGFBP-6 demon-
strated significantly decreased (P=0·03) renal mRNA
levels (Fig. 2A and B). IGF-I-infused animals demon-
strated significantly decreased renal IGFBP-6 mRNA
levels (P=0·001) (Fig. 2B).
In the EGF/IGF-I infusion group, the renal IGFBP-4
mRNA levels were significantly increased (P=0·05) (Fig.
2A), whereas renal IGFBP-6 and IGF-II/Man-6-P recep-
tor mRNA levels were significantly decreased (P=0·02
and P=0·01 respectively) (Fig. 2B). IGFBP-6 mRNA
Table 2 Serum IGF-I and serum IGFBP levels (all meanS.E.M., n=8) in adult female rats after 7 days of placebo, EGF, IGF-I or EGF+ IGF-I
treatment
Placebo control EGF IGF-I EGF+IGF-I
IGF-I (µ/l) 43815 39625 153792*** 96494*#
IGFBP-3 (AU/mm2) 180·412·9 78·88·6*** 325·817·0*** 213·932·1
IGFBP-1 and -2 (AU/mm2) 36·75·8 40·65·8 90·710·7** 112·120·0**
IGFBP-4 (AU/mm2) 22·41·7 36·93·4* 19·22·2 40·75·0**
*P0·02, **P0·008, ***P0·001, when compared with placebo controls.
#P=0·01, when compared with the IGF-I infusion group.
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levels in the EGF/IGF-I infusion group were the result of
a significant interaction between EGF and IGF-I that
could be significantly attributed to EGF (P=0·04) and
IGF-I (P=0·006).
Renal IGF-I and IGF-II mRNA could not be reliably
quantified in any of the groups.
Discussion
In the present study we investigated the effects of short-
term systemic treatment with EGF and/or IGF-I on
growth parameters and hepatic and renal expression of the
IGF system genes in young adult female rats.
EGF infusion did not show any effect on body weight
gain. This is in agreement with our earlier EGF infusion
study in young adult male rats where EGF administration
for 4 weeks (400 µg/kg/day), did not significantly change
body weight gain (Frystyk et al. 1996). In newborn
animals, EGF treatment (doses 50–1000 µg/kg/day) re-
sults in retarded organ and body growth (Hoath et al.
1988). This growth retardation was most prominent when
EGF was applied directly after birth and persisted until
weaning (Hoath 1986). EGF is normally present in very
Figure 1 (A) Hepatic IGFBP-1, -2, -3 and -4 mRNA levels in young adult female rats, infused for 7 days with
acetic acid (placebo control), 30 g/kg/day EGF, 400 g/kg/day IGF-I and 30 g/kg/day EGF+400 g/kg/day
IGF-I. Values are based on quantitations of Northern blots where each lane contained 20 g of total RNA and
was compensated for RNA loading differences. Values are represented as meansS.E.M. (n=8) and expressed
relative to placebo control. *P=0·03, **P=0·01, ***P=0·001, statistical significance level between the
indicated group and the placebo control. (B) Hepatic IGFBP-5, -6, IGF-I and IGF-II/Man-6-P receptor mRNA
levels in young adult female rats, infused for 7 days with acetic acid (placebo control), 30 g/kg/day EGF,
400 g/kg/day IGF-I and 30 g/kg/day EGF+400 g/kg/day IGF-I. Values represent the quantified outcome
of RT-PCR reactions, compensated for differences in efficiency and the amount of starting material. Values are
represented as meansS.E.M. (n=8) and expressed relative to placebo control. *P=0·05, statistical significance
level between the indicated group and the placebo control.
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low (0·1<2 µg/l) quantities in circulation (Nexø et al.
1992). Systemic administration at the doses used in these
studies, therefore, represents a pharmacological situation.
In contrast to EGF infusion, IGF-I infusion resulted
in a significantly increased body weight gain. This is in
agreement with an earlier study where 240 µg/rat/day
IGF-I was infused for 14 days in 6-week-old female rats
(van Neck et al. 1997). EGF/IGF-I infusion also resulted
in a significantly increased body weight gain. However,
weight gain in this group did not significantly differ from
the IGF-I infusion group.
Liver weight was not increased in any of the growth
factor treatment regimens. This is in agreement with
earlier studies (Frystyk et al. 1996, van Neck et al. 1997).
In contrast, kidney weight was significantly increased in
the IGF-I and in the EGF/IGF-I treatment groups but not
by EGF treatment alone. The observed effect of IGF-I
infusion on kidney weight is consistent with earlier
findings (Gruaz et al. 1997, van Neck et al. 1997), as is the
ineffectiveness of EGF on kidney growth (Frystyk et al.
1996). This is in contrast to the findings of Breider et al.
(1996) who infused male and female animals with
Figure 2 (A) Kidney IGFBP-1, -2, -3, -4 and -5 mRNA levels in young adult female rats, infused for 7 days
with acetic acid (placebo control), 30 g/kg/day EGF, 400 g/kg/day IGF-I and 30 g/kg/day EGF+
400 g/kg/day IGF-I. Values are based on quantitations of Northern blots where each lane contained 20 g
of total RNA and was compensated for RNA loading differences. Values are represented as meansS.E.M.
(n=8) and expressed relative to placebo control. *P=0·05, **P=0·03, statistical significance level between
the indicated group and the placebo control. (B) Kidney IGFBP-6, IGF-I receptor and IGF-II/Man-6-P
receptor mRNA levels in young adult female rats, infused for 7 days with acetic acid (placebo control),
30 g/kg/day EGF, 400 g/kg/day IGF-I and 30 g/kg/day EGF+400 g/kg/day IGF-I. Values represent the
quantitated outcome of RT-PCR reactions, compensated for differences in efficiency and the amount of
starting material. Values are represented as meansS.E.M. (n=8) and expressed relative to placebo control.
*P=0·02, **P=0·01, ***P=0·005, statistical significance level between the indicated group and the placebo
control.
J W VAN NECK and others · IGF-system expression after EGF and/or IGF infusion120
www.endocrinology.orgJournal of Endocrinology (2000) 165, 115–122
100 µg/kg/day EGF for 4 weeks and observed both
liver and kidney enlargement. Interestingly, in this
study, kidney enlargement only was observed in female
animals.
The effects of systemic EGF administration have been
extensively studied in neonatal rats. In newborn animals
EGF administration reduced the circulatory IGF-I levels
but increased the mRNA and protein expression of
IGFBP-1 (Murray et al. 1993). Older animals demon-
strated strongly diminished responses to EGF infusion. In
our study, EGF infusion did not affect the 30 kDa IGFBPs
(IGFBP-1 and -2) and the hepatic mRNA expression did
not change. In contrast, treatment with EGF/IGF-I
increased the 30 kDa protein band and the hepatic
IGFBP-1 and -2 mRNA expression. IGFBP-4 was
increased in both the EGF and EGF/IGF-I infusion
groups whereas the corresponding hepatic mRNA levels
were unchanged. EGF infusion reduced IGFBP-3 levels.
This was also observed in previous studies (Frystyk et al.
1996, Vinter-Jensen et al. 1996). In addition, the EGF/
IGF-I infusion group also revealed reduced IGFBP-3
levels when compared with the IGF-I infusion group,
however, with unchanged hepatic IGFBP-3 mRNA
levels. This is in contrast to in vitro studies where a 5-fold
reduction in IGFBP-3 mRNA was demonstrated in
cultured keratinocytes by treatment with EGF (Wraight &
Werther 1995, Edmondson et al. 1999). In our in vivo
experiment, a post-transcriptional event probably under-
lies the observed decrease in IGFBP-3, as hepatic
IGFBP-3 mRNA was not significantly decreased in the
EGF and EGF/IGF-I infusion groups. To test the effect of
EGF on IGFBP-3 stability, 125I-IGFBP-3 was incubated
with different doses of EGF ranging from 0·001 to
500 µg/ml. EGF had no effect on IGFBP-3 proteolysis in
vitro excluding a direct IGFBP-3 proteolytic effect (data
not shown). EGF infusion did not influence the hepatic
mRNA levels of the other members of the IGF-system.
Barreca described a dose-dependent stimulation of IGF-I
secretion in cultured liver cells, already detectable at a
concentration of 30 µg/l (Barreca et al. 1992). In our rat
in vivo experiments, however, the EGF infusion group did
not show a stimulatory effect on circulatory IGF-I levels,
nor did EGF infusion significantly increase hepatic IGF-I
mRNA expression.
In the IGF-I infusion group, circulatory levels of the
30 kDa IGFBPs (IGFBP-1 and -2) and IGFBP-3 were
significantly increased. These changes were reflected by
corresponding changes in the hepatic mRNA profiles of
IGFBP-1 and -3. In a previous study, IGF-I infusion for
14 days also upregulated hepatic IGFBP-3 mRNA levels
(van Neck et al. 1997). Compared with the IGF-I infusion
group, IGFBP-3 levels in the EGF/IGF-I infusion group
were significantly decreased. Decreased IGFBP-3 levels
may result in a release of free, biodegradable IGF-I which
may explain the decreased circulating pool of IGF-I as
observed in the EGF/IGF-I group.
In the IGF-I infusion group, circulatory IGF-I levels
were increased 3-fold, achieving levels similar to those
measured in an earlier IGF-I infusion study (van Neck
et al. 1997). In the EGF/IGF-I infusion group, circulatory
IGF-I levels were significantly reduced. As identical
amounts of IGF-I were infused in both the EGF/IGF-I
and IGF-I group, EGF, therefore, seemed to decrease the
amount of circulatory IGF-I without affecting its mRNA
level.
In kidney, only IGFBP-6 mRNA levels were lower
in the IGF-I treatment group. IGF-I infusion did not
influence the local expression of the other IGF-system
members despite its pronounced effects on kidney
growth.
To our knowledge the present study is the first to
investigate the very complex interaction or cross-talk
between the EGF and the IGF-system in vivo. IGF-I and
EGF/IGF-I infusions significantly increased circulatory
IGF-I but had no effect on hepatic IGF-I levels. Kidney
weight was also significantly increased in these groups.
EGF infusion lowered circulatory IGFBP-3 without an
effect on hepatic IGFBP-3 mRNA levels.
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